乳腺癌多基因检测的再思考:机遇与挑战
Concerns and perspectives for multigene tests of breast cancer: opportunities and challenges

DOI: 10.6040/j.issn.1671-7554.0.2017.1036

Keywords: 多基因检测,,,挑战,机遇,乳腺癌,Oncotype DX^？,MammaPrint^？,
Multigene test,,,Challenges,Breast cancer,Oncotype DX^？,MammaPrint^？,Opportunities

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Cossetti RJ, Tyldesley SK, Speers CH, et al. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008[J]. J Clin Oncol, 2015, 33(1): 65-73.
[2]	Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer[J]. J Clin Oncol, 2006, 24(23): 3726-3734.
[3]	van de Vijver MJ, He YD, vant VLJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med, 2002, 347(25): 1999-2009.
[4]	Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci U S A, 2003, 100(14): 8418-8423.
[5]	Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13: IL17BR are complementary prognostic factors in early stage breast cancer[J]. Clin Cancer Res, 2008, 14(9): 2601-2608.
[6]	Gong G, Kwon MJ, Han J, et al. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer[J]. Sci Rep, 2017, 7: 45554. doi: 10.1038/srep45554.
[7]	EL Baiomy MA1, El Kashef WF. ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy[J]. Asian Pac J Cancer Prev, 2017, 18(2): 507-513.
[8]	Haynes B, Sarma A, Nangia-Makker P, et al. Breast cancer complexity: implications of intratumoral heterogeneity in clinical management[J]. Cancer Metastasis Rev, 2017, 36(3): 547-555.
[9]	Krop I, Ismaila N, Stearns V. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary[J]. J Oncol Pract, 2017: JOP2017024646. doi: 10.1200/JOP.2017.024646.[Epub ahead of print]
[10]	Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy[J]. J Clin Oncol, 2008, 26(2): 246-252.
[11]	Buyse M, Loi S, vant VL, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J]. J Natl Cancer Inst, 2006, 98(17): 1183-1192.
[12]	Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study[J]. Breast Cancer Res Treat, 2009, 116(2): 295-302.
[13]	Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20[J]. Breast Cancer Res Treat, 2011, 127(1): 133-142.
[14]	Iwamoto T, Lee JS, Bianchini G, et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations[J]. Breast Cancer Res Treat, 2011, 130(1): 155-164.
[15]	Ribnikar D, Sousa B, Cufer T, et al. Extended adjuvant endocrine therapy - a standard to all or some[J]. Breast, 2017, 32: 112-118. doi: 10.1016/j.breast.2017.01.004
[16]	Hequet D, Callens C, Gentien D, et al. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna<sup>？</sup> Test in the management of early-stage breast cancers[J]. PLoS One, 2017, 12(10): e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017.
[17]	Xu YC, Zhang FC, Li JJ, et al. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients[J]. Oncol Rep, 2015, 34(4): 1883-1894.
[18]	He Q, Peng B, Zhuang D, et al. Clinicopathological significance of β-tubulin isotype III gene expression in breast cancer patients[J]. Cancer Biomark, 2015, 15(6): 823-831.
[19]	Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer[J]. JAMA, 2011, 305(18): 1873-1881.
[20]	Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98[J]. J Clin Oncol, 2013, 31(7): 860-867.
[21]	马榕, 王建丽. 乳腺癌多基因检测及其临床意义[J]. 中国实用外科杂志, 2015, 35(7): 701-703. MA Rong, WANG Jianli. Multi-gene testing in breast cancer and clinical significance[J]. Chinese Journal of Practical Surgery, 2015, 35(7): 701-703.
[22]	Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents[J]. Cancer Discov, 2012, 2(4): 366-375.
[23]	Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351(27): 2817-2826.
[24]	Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes[J]. J Clin Oncol, 2009, 27(8): 1160-1167.
[25]	Bianchini G, Iwamoto T, Qi Y, et al. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer[J]. Cancer Res, 2010, 70(21): 8852-8862.
[26]	Jinih M, Relihan N, Corrigan MA, et al. Extended adjuvant endocrine therapy in breast cancer: evidence and update — a review[J]. Breast J, 2017, 23(6): 694-705.
[27]	Wolmark N, Mamounas EP, Baehner FL, et al. Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression(ESR1)on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: results from NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14[J]. J Clin Oncol, 2016, 34(20): 2350-2358.
[28]	He DX, Wu XL, Lu CX, et al. Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer[J]. Oncol Rep, 2017, 38(6): 3392-3402.
[29]	Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed[M]. New York: Springer International Publishing, 2017.
[30]	Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J]. J Clin Oncol, 2007, 25(33): 5287-5312.
[31]	Cardoso F, vant Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729.
[32]	江泽飞, 许凤锐. 乳腺癌精准医学: 热潮中的冷思考[J]. 中华外科杂志, 2017, 55(2): 90-94. JIANG Zefei, XU Fengrui. Calm thinking for precision medicine of breast cancer in the boom[J]. Chinese Journal of Surgery, 2017, 55(2): 90-94.
[33]	Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen[J]. Ann Oncol, 2012, 23(11): 2866-2873.
[34]	Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer[J]. Lancet, 2005, 365(9460): 671-679.
[35]	Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers[J]. J Clin Oncol, 2006, 24(11): 1656-1164.
[36]	Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[37]	Abramovitz M, Krie A, Dey N, et al. Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy[J]. Curr Opin Oncol, 2016, 28(6): 461-468.
[38]	Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-Gene expression assay in breast cancer[J]. N Engl J Med, 2015, 373(21): 2005-2014.
[39]	Gy？rffy B, Hatzis C, Sanft T, et al. Multigene prognostic tests in breast cancer: past, present, future[J]. Breast Cancer Res, 2015, 17: 11. doi: 10.1186/s13058-015-0514-2.
[40]	Jahn B, Rochau U, Kurzthaler C, et al. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant Online[J]. BMC Cancer, 2017, 17(1): 685.

Full-Text